Homepage Top Section2

LXE408 was discovered at Novartis with the financial backing of the Wellcome Trust. According to Novartis, more than a billion people across the world are at risk of

Under a strategic collaboration agreement, the companies will involve in the discovery, development and commercialisation of novel Bicycle Therapeutics-based immuno-oncology therapies. The deal allows Bicycle to explore its

Under the research collaboration, the companies will evaluate Clover’s protein-based coronavirus vaccine candidate (COVID-19 S-Trimer) with GSK’s pandemic adjuvant system. GSK’s pandemic adjuvant system will help further assess

Claimed to be the first FDA-approved intravenous (IV) treatment for migraine prevention, the Vyepti will be available from April and the recommended dose is 100mg for every three

As per terms of the deal, Immatics will secure an upfront payment of up to $50m from GSK for two initial programmes. Immatics has an option to secure

The approval from the European Commission (EC) makes VYNDAQEL the first and only treatment for patients with ATTR-CM in the European Union (EU). Considered to be a rare,

The company will invest around $109m to develop the 135,000ft² gene therapy manufacturing facility. North Carolina Governor Roy Cooper said: “With our powerhouse research centres and highly-skilled workforce,

Beovu is claimed to be the first EC-approved anti-VEGF treatment to show better resolution of retinal fluid (IRF/SRF) against aflibercept. Wet AMD, a chronic and degenerative eye disease,

The company said that 26% of patients with previously treated advanced or metastatic renal cell carcinoma are alive at five years of treatment with Opdivo. According to Bristol-Myers